Page 32 - Read Online

Cheng et al. Cancer Drug Resist. 2025;8:46 Page 25 of 28

91. Mao C, Deng F, Zhu W, et al. In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins
for enhanced cancer immunotherapy. Nat Commun. 2024;15:9723. DOI PubMed PMC
92. Xue F, Ren X, Kong C, et al. Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Mater Today
Bio. 2024;28:101239. DOI PubMed PMC
93. Bigos KJ, Quiles CG, Lunj S, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve
treatment outcome in solid tumours. Front Oncol. 2024;14:1331355. DOI PubMed PMC
94. Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer.
2019;18:10. DOI PubMed PMC
95. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 2014;211:781-90. DOI PubMed PMC
96. Suresh S, Chen B, Zhu J, et al. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer.
2020;1:533-45. DOI PubMed PMC
97. Ding XC, Wang LL, Zhang XD, et al. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia. J
Hematol Oncol. 2021;14:92. DOI PubMed PMC
98. You L, Wu W, Wang X, et al. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev. 2021;41:1622-43. DOI
PubMed
99. Alves CC, Donadi EA, Giuliatti S. Structural characterization of the interaction of hypoxia inducible factor-1 with its hypoxia responsive
element at the -964G > a variation site of the HLA-G promoter region. Int J Mol Sci. 2021;22:13046. DOI PubMed PMC
100. Wang S, Wang J, Xia Y, et al. Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects. J Transl Med.
2024;22:130. DOI PubMed PMC
101. Labiano S, Palazón A, Bolaños E, et al. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune
escape mechanism. Oncoimmunology. 2016;5:e1062967. DOI PubMed PMC
102. Hakimi AA, Attalla K, DiNatale RG, et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy
response. Nat Commun. 2020;11:4168. DOI PubMed PMC
103. Wu F, Sun G, Nai Y, Shi X, Ma Y, Cao H. NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway
in colorectal cancer progression and metastatsis. Cell Death Discov. 2024;10:241. DOI PubMed PMC
104. Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther.
2024;32:4235-55. DOI PubMed PMC
105. Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L. NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune
evasion and therapeutic resistance. Front Immunol. 2025;16:1518664. DOI PubMed PMC
106. Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape.
Oncol Lett. 2020;19:2595-601. DOI PubMed PMC
107. Mortezaee K, Majidpoor J. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: updated. J Cell
Mol Med. 2023;27:311-21. DOI PubMed PMC
108. Ho JJD, Balukoff NC, Cervantes G, Malcolm PD, Krieger JR, Lee S. Oxygen-sensitive remodeling of central carbon metabolism by
archaic eIF5B. Cell Rep. 2018;22:17-26. DOI PubMed PMC
109. Yu A, Fu L, Jing L, et al. Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated
immune responses and enhancing the eIF5B-PD-L1 axis. Cell Death Differ. 2025;32:776-91. DOI PubMed PMC
110. Palazón A, Martínez-Forero I, Teijeira A, et al. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional
CD137 (4-1BB) for immunotherapy. Cancer Discov. 2012;2:608-23. DOI PubMed
111. Walter Jackson Iii, Yang Y, Salman S, et al. Pharmacologic HIF stabilization activates costimulatory receptor expression to increase
antitumor efficacy of adoptive T cell therapy. Sci Adv. 2024;10:eadq2366. DOI PubMed PMC
112. Jiang Z, Fang Z, Hong D, Wang X. Cancer immunotherapy with “vascular-immune” crosstalk as entry point: associated mechanisms,
therapeutic drugs and nano-delivery systems. Int J Nanomedicine. 2024;19:7383-98. DOI PubMed PMC
113. Mattila P, Majuri ML, Mattila PS, Renkonen R. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and
VCAM-1, is linked to protein kinase C activation. Scand J Immunol. 1992;36:159-65. DOI PubMed
114. Xia P, Gamble JR, Rye KA, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase
pathway. Proc Natl Acad Sci U S A. 1998;95:14196-201. DOI PubMed PMC
115. Liu B, Gao J, Lyu BC, et al. Expressions of TGF-β2, bFGF and ICAM-1 in lens epithelial cells of complicated cataract with silicone oil
tamponade. Int J Ophthalmol. 2017;10:1034-9. DOI PubMed PMC
116. Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Nat Med. 2014;20:607-15. DOI PubMed PMC
25